Search Results for

S2308

RANDOMIZED PHASE III STUDY OF MOSUNETUZUMAB VS. RITUXIMAB FOR LOW TUMOR BURDEN FOLLICULAR LYMPHOMA

Continue Reading »

---

M22-003

Study of Subcutaneous Epcoritamab in Combination with Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants with Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Continue Reading »

---

GO44145

A Phase III, Multicenter, Randomized, Open‑Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA‑R‑CHP in Previously Untreated Patients with Large B-Cell Lymphoma

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Bladder/Urinary Tract Cancer  (4)    Adjuvant  (1)    Metastatic  (1) Brain  (9)    Glioblastoma Multiforme (GBM)  (2)    Other Brain Tumors  (3) Breast  (15)    Breast Cancer Adjuvant  (1)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (17) Carcinoid Tumors  (2) Colorectal Cancer  (5)    Rectal Neoadjuvant  (1) Esophageal Cancer  (5) Gall Bladder/ Biliary Tract Cancer  (1) Gastric Cancer  (4) Head/Neck Cancer  (8) Leukemia  (6)    Acute Myeloid Leukemia (AML)  (2)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (3) Lung Cancer  (17)    Non-Small Cell Lung Cancer  (13)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (2)       Adjuvant Treatment for Resected NSCLC  (1)    Small Cell Lung Cancer  (3)       Extensive Stage SCLC  (1) Lymphoma  (3)    Non-Hodgkin’s Lymphoma  (3)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (2) MATCH Trial  (5) Melanoma  (3)    Metastatic  (1) Misc. Gynecology  (4) Multiple Myeloma  (3) Ovarian  (2) Pancreatic  (9)    Metastatic Disease  (1) Prostate  (12) Renal Cell/Kidney Cancer  (2) Sarcoma  (1) Thyroid  (1)